AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11522565 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber, high-fruit-and-vegetable, low-fat diet (4.30 g/MJ fiber, 0.84 servings/MJ fruit and vegetables, 20% of energy from fat)
Number of subjects: 2079
Study 11522565 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard diet)
Number of subjects: 2079
Study 9051389 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg ALA daily for 4 months
Number of subjects: 73
Study 9051389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 8330461 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine (oral doses)
Number of subjects: 0
Study 8330461 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (oral doses)
Number of subjects: 0
Study 8330461 — intervention group
Group type: COMPARATOR
Intervention: Amantadine (baseline)
Number of subjects: 0
Study 2451815 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine (80 mg i.v.)
Number of subjects: 0
Study 2451815 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine (30 mg i.v.)
Number of subjects: 0
Study 2451815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2551070 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 XaI U/kg b.w. twice daily Logiparin
Number of subjects: 20
Study 2551070 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 XaI U/kg b.w. once daily Logiparin
Number of subjects: 20
Study 2551070 — intervention group
Group type: EXPERIMENTAL
Intervention: Logiparin treatment
Number of subjects: 20
Study 2551070 — intervention group
Group type: EXPERIMENTAL
Intervention: Logiparin
Number of subjects: 20
Study 31933342 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-strap bag
Number of subjects: 16
Study 31933342 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-strap bag
Number of subjects: 16
Study 31933342 — intervention group
Group type: COMPARATOR
Intervention: Unloaded condition
Number of subjects: 16
Study 28702852 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated TD/IMB intervention (experimental group)
Number of subjects: 84
Study 28702852 — intervention group
Group type: COMPARATOR
Intervention: IMB-guided sexual risk reduction (control group)
Number of subjects: 84
Study 26498746 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 128
Study 26498746 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 128
Study 23677816 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care intervention including medication review, education on osteoporosis, risk factors, lifestyle modifications, goals of therapy, side effects, and importance of medication adherence at months 0, 3, 6, and 12
Number of subjects: 198
Study 23677816 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care intervention
Number of subjects: 198
Study 23677816 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 198
Study 21308343 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational nursing intervention during hospitalization followed by telephone monitoring after discharge (Intervention Group - IG)
Number of subjects: 111
Study 21308343 — intervention group
Group type: COMPARATOR
Intervention: In-hospital intervention only (Control Group - CG)
Number of subjects: 111
Study 19824379 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus ovestin (daily intravaginal administration for 2 weeks, then twice a week)
Number of subjects: 102
Study 19824379 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 102
Study 17525699 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck muscle training
Number of subjects: 118
Study 15208504 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐L,L‐EC scan
Number of subjects: 82
Study 15208504 — intervention group
Group type: COMPARATOR
Intervention: 99mTc‐DMSA scan
Number of subjects: 82
Study 11588692 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramoplanin 100 mg
Number of subjects: 68
Study 11588692 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramoplanin 400 mg
Number of subjects: 68
Study 11588692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 9613276 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural blockade with 0.9% saline (16 ml) prior to incision and 0.5% bupivacaine (15 ml) + fentanyl 50 micrograms (1 ml) prior to closure.
Number of subjects: 50
Study 9613276 — intervention group
Group type: COMPARATOR
Intervention: Epidural blockade with 0.5% bupivacaine (15 ml) + fentanyl 50 micrograms (1 ml) prior to incision and 0.9% saline prior to closure.
Number of subjects: 50
Study 7570844 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin treatment
Number of subjects: 0
Study 2782692 — intervention group
Group type: COMPARATOR
Intervention: Seldinger technique (Seldicath Plastimed, FG 3, 80 mm long; group S; n = 30)
Number of subjects: 60
Study 2782692 — intervention group
Group type: EXPERIMENTAL
Intervention: New arterial catheter (Arrow, Critikon, gauge 20, 44 mm long; group A; n = 30)
Number of subjects: 60
Study 766679 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergy prick tests
Number of subjects: 3101
Study 30339878 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐piece acrylic intraocular lens (IOL; SA60AT; Alcon Laboratories)
Number of subjects: 930
Study 30339878 — intervention group
Group type: EXPERIMENTAL
Intervention: Three‐piece acrylic IOL (MA60AS; Alcon Laboratories)
Number of subjects: 930
Study 30339878 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsular tension ring (randomized within pseudoexfoliation group)
Number of subjects: 930
Study 30339878 — intervention group
Group type: COMPARATOR
Intervention: Control group (cataract without pseudoexfoliation)
Number of subjects: 930
Study 27349220 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume oral sulfate solution (OSS)
Number of subjects: 210
Study 27349220 — intervention group
Group type: COMPARATOR
Intervention: 4-L polyethylene glycol (PEG)
Number of subjects: 210
Study 26297239 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge medication counselling and medication review by a clinical pharmacist
Number of subjects: 183
Study 26297239 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 183
Study 23947774 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured communication approach (DIALOG) with principles of solution-focused therapy, 6 meetings over 6 months
Number of subjects: 96
Study 23947774 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 96
Study 21324674 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA) 4 mg intravenous every 3 months for 2 years (arm A)
Number of subjects: 439
Study 21324674 — intervention group
Group type: COMPARATOR
Intervention: Control group (arm B) receiving ZA 1 year after randomization
Number of subjects: 439
Study 19770811 — intervention group
Group type: EXPERIMENTAL
Intervention: Johnson & Johnson ACUVUE OASYS with HYDRACLEAR PLUS (OAS)
Number of subjects: 40
Study 19770811 — intervention group
Group type: EXPERIMENTAL
Intervention: CIBA Vision Night & Day (ND)
Number of subjects: 40
Study 19770811 — intervention group
Group type: COMPARATOR
Intervention: CIBA Vision O2OPTIX (O2)
Number of subjects: 40
Study 19770811 — intervention group
Group type: EXPERIMENTAL
Intervention: Johnson & Johnson ACUVUE ADVANCE with HYDRACLEAR (ADV)
Number of subjects: 40
Study 19770811 — intervention group
Group type: EXPERIMENTAL
Intervention: Bausch & Lomb PureVision (PV)
Number of subjects: 40
Study 17296236 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine administered into the tonsillar region
Number of subjects: 60
Study 17296236 — intervention group
Group type: COMPARATOR
Intervention: 2 ml 0.9% saline administered into the tonsillar region
Number of subjects: 60
Study 15538230 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchful waiting policy
Number of subjects: 191
Study 11495480 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine challenge
Number of subjects: 105
Study 9721054 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation on both quadriceps muscles for 8 weeks (group EXP)
Number of subjects: 14
Study 9721054 — intervention group
Group type: COMPARATOR
Intervention: No electrical stimulation (group CONT)
Number of subjects: 14
Study 7991755 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary community-based team (Early Intervention Service)
Number of subjects: 100
Study 7991755 — intervention group
Group type: COMPARATOR
Intervention: Conventional hospital-based psychiatric services
Number of subjects: 100
Study 3141220 — intervention group
Group type: EXPERIMENTAL
Intervention: hFSH/hMG on days 3 and 4 of the cycle followed by two ampules of hMG daily
Number of subjects: 11
Study 3141220 — intervention group
Group type: COMPARATOR
Intervention: Constant daily dose of 2 ampules of hMG
Number of subjects: 11
Study 3141220 — intervention group
Group type: EXPERIMENTAL
Intervention: hFSH/hMG
Number of subjects: 11
Study 3141220 — intervention group
Group type: COMPARATOR
Intervention: hMG
Number of subjects: 11
Study 3141220 — intervention group
Group type: EXPERIMENTAL
Intervention: hFSH/hMG and hMG
Number of subjects: 11
Study 31141079 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound guided coil plus cyanoacrylate
Number of subjects: 32
Study 31141079 — intervention group
Group type: COMPARATOR
Intervention: Conventional cyanoacrylate technique
Number of subjects: 32
Study 28782603 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural Analgesia (EA)
Number of subjects: 87
Study 26439234 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with Animal-Assisted Therapy (E+ATT; n = 8)
Number of subjects: 15
Study 26439234 — intervention group
Group type: COMPARATOR
Intervention: Exercise only (E; n = 7)
Number of subjects: 15
Study 25468616 — intervention group
Group type: EXPERIMENTAL
Intervention: Late umbilical cord clamping (3 minutes after delivery)
Number of subjects: 56
Study 25468616 — intervention group
Group type: COMPARATOR
Intervention: Early umbilical cord clamping (10 seconds after delivery)
Number of subjects: 56
Study 25468616 — intervention group
Group type: EXPERIMENTAL
Intervention: Late umbilical cord clamping
Number of subjects: 56
Study 25468616 — intervention group
Group type: COMPARATOR
Intervention: Early umbilical cord clamping
Number of subjects: 56
Study 21723684 — intervention group
Group type: EXPERIMENTAL
Intervention: Low volume contrast media (0.5 ml/kg) and low kV (100) in group B
Number of subjects: 41
Study 21723684 — intervention group
Group type: COMPARATOR
Intervention: Standard volume contrast media (1 ml/kg) and standard kV (120) in group A
Number of subjects: 41
Study 19114966 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU) daily for five days during two menstrual cycles
Number of subjects: 72
Study 19114966 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical in appearance to vitamin E) daily for five days during two menstrual cycles
Number of subjects: 72
Study 17689112 — intervention group
Group type: EXPERIMENTAL
Intervention: PTA (Percutaneous Transluminal Angioplasty)
Number of subjects: 20
Study 17689112 — intervention group
Group type: EXPERIMENTAL
Intervention: PTA+EVBT (Percutaneous Transluminal Angioplasty + Endovascular Brachytherapy)
Number of subjects: 20
Study 15322504 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (dalteparin)
Number of subjects: 37
Study 15322504 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 37
Study 11522160 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based lay health worker outreach
Number of subjects: 1599
Study 11522160 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based provider training and reminder system
Number of subjects: 1599
Study 11522160 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigator for follow-up of abnormal screening results
Number of subjects: 1599
Study 11522160 — intervention group
Group type: COMPARATOR
Intervention: Non-English-speaking Latinas
Number of subjects: 1599
Study 11522160 — intervention group
Group type: COMPARATOR
Intervention: Non-English-speaking Chinese women
Number of subjects: 1599
Study 11522160 — intervention group
Group type: COMPARATOR
Intervention: Blacks
Number of subjects: 1599
Study 9509802 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirilazad mesylate (6 mg/kg per day)
Number of subjects: 0
Study 9509802 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 8047199 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingertip pulsed Doppler (FPD) 5 MHz probe
Number of subjects: 12
Study 8047199 — intervention group
Group type: COMPARATOR
Intervention: Blind standard punctures
Number of subjects: 12
Study 2646753 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (40 mg on days 1 and 2, additional 20 mg on day 3 if necessary)
Number of subjects: 198
Study 2646753 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (1,000 mg on days 1 and 2, additional 500 mg on day 3 if necessary)
Number of subjects: 198
Study 31306607 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized/predictive interface
Number of subjects: 42
Study 31306607 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized/static interface
Number of subjects: 42
Study 31306607 — intervention group
Group type: COMPARATOR
Intervention: Random/static interface
Number of subjects: 42
Study 31306607 — intervention group
Group type: COMPARATOR
Intervention: Random/predictive interface
Number of subjects: 42
Study 27416774 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional Oblique Transection Double Stapling Technique (IOT-DST)
Number of subjects: 15
Study 24359098 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary sinus packing with epinephrine hydrochloride-soaked cotton pledgets (Group 1)
Number of subjects: 57
Study 24359098 — intervention group
Group type: COMPARATOR
Intervention: No packing (Group 2)
Number of subjects: 57
Study 23543447 — intervention group
Group type: COMPARATOR
Intervention: Adefovir (ADV) monotherapy
Number of subjects: 206
Study 23543447 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (LAM) monotherapy
Number of subjects: 206
Study 23543447 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (LAM + ADV)
Number of subjects: 206
Study 23543447 — intervention group
Group type: COMPARATOR
Intervention: LAM group
Number of subjects: 206
Study 20887516 — intervention group
Group type: EXPERIMENTAL
Intervention: Aegis Ortho® (ACP-containing orthodontic composite)
Number of subjects: 14
Study 20887516 — intervention group
Group type: COMPARATOR
Intervention: Concise® (resin-based orthodontic composite)
Number of subjects: 14
Study 17710487 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) simulator training using Procedicus MIST, 2 hours per day for 2 days
Number of subjects: 35
Study 17710487 — intervention group
Group type: EXPERIMENTAL
Intervention: Box trainer training, 2 hours per day for 2 days
Number of subjects: 35
Study 17710487 — intervention group
Group type: COMPARATOR
Intervention: Control group watched an educational video for 30 minutes
Number of subjects: 35
Study 15756221 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG) plus 70% lactulose (1 mL/kg/day)
Number of subjects: 84
Study 15756221 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus 70% lactulose (1 mL/kg/day)
Number of subjects: 84
Study 12934177 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz plus indinavir
Number of subjects: 517
Study 12934177 — intervention group
Group type: EXPERIMENTAL
Intervention: nelfinavir plus indinavir
Number of subjects: 517
Study 12934177 — intervention group
Group type: COMPARATOR
Intervention: indinavir
Number of subjects: 517
Study 11761737 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-session multicomponent program (n = 25)
Number of subjects: 114
Study 11761737 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-session multicomponent program (n = 31)
Number of subjects: 114
Study 11761737 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-session multicomponent plus self-help manual program (n = 25)
Number of subjects: 114
Study 11761737 — intervention group
Group type: EXPERIMENTAL
Intervention: self-help-manual-only program (n = 33)
Number of subjects: 114
Study 11761737 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 48)
Number of subjects: 114
Study 8859237 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg/kg bolus followed by saline infusion)
Number of subjects: 28
Study 8859237 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1.0 mg/kg bolus followed by 65 micrograms/kg/min infusion)
Number of subjects: 28
Study 8859237 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Midazolam and Propofol
Number of subjects: 28
Study 8396100 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg daily for 3 days)
Number of subjects: 154
Study 8396100 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin (30 mg/kg/day for 10 days in three divided doses; children > 20 kg received 250 mg tid daily)
Number of subjects: 154
Study 8396100 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 154
Study 8396100 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 154
Study 3523741 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg X 2)
Number of subjects: 42
Study 3523741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 28795342 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol therapy (50,000 IU once a week for 12 weeks)
Number of subjects: 119
Study 25125300 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk plaque detected by coronary CTA
Number of subjects: 472
Study 25125300 — intervention group
Group type: COMPARATOR
Intervention: Significant CAD (≥50% stenosis)
Number of subjects: 472
Study 25125300 — intervention group
Group type: COMPARATOR
Intervention: Clinical risk assessment (age, sex, number of cardiovascular risk factors)
Number of subjects: 472
Study 22965507 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated aspiration and alcohol instillation sclerotherapy
Number of subjects: 67
Study 22965507 — intervention group
Group type: COMPARATOR
Intervention: Single-session alcohol retention sclerotherapy
Number of subjects: 67
Study 22965507 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study 20951260 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboelastometrically guided transfusion algorithm
Number of subjects: 56
Study 20951260 — intervention group
Group type: COMPARATOR
Intervention: Routine transfusion practices (clinical judgment-guided transfusion)
Number of subjects: 56
Study 17595270 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management program (Bright Bodies)
Number of subjects: 209
Study 16164121 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 100 mg/day
Number of subjects: 62
Study 16164121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 12078940 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg + Amlodipine 5 mg (BZ+AM)
Number of subjects: 405
Study 12078940 — intervention group
Group type: COMPARATOR
Intervention: Captopril 50 mg + Hydrochlorothiazide 25 mg (CP+HT)
Number of subjects: 405
Study 11008323 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione (5 g immediately before cisplatin)
Number of subjects: 20
Study 11008323 — intervention group
Group type: COMPARATOR
Intervention: Control (2000 ml electrolyte infusion before and 2000 ml normal saline after cisplatin)
Number of subjects: 20
Study 8536820 — intervention group
Group type: EXPERIMENTAL
Intervention: Voglibose 0.5 mg
Number of subjects: 72
Study 8536820 — intervention group
Group type: EXPERIMENTAL
Intervention: Voglibose 1.0 mg
Number of subjects: 72
Study 8536820 — intervention group
Group type: EXPERIMENTAL
Intervention: Voglibose 1.0 mg (3 times daily for 7 days)
Number of subjects: 72
Study 8536820 — intervention group
Group type: EXPERIMENTAL
Intervention: Voglibose 2.0 mg
Number of subjects: 72
Study 8536820 — intervention group
Group type: EXPERIMENTAL
Intervention: Voglibose 5.0 mg
Number of subjects: 72
Study 8536820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 2621331 — intervention group
Group type: EXPERIMENTAL
Intervention: HCG injection for ovulation induction
Number of subjects: 77
Study 859943 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily application of INH 400 mg, rifampicin 450-600 mg, and myambutol 25 mg/kg for the first two months followed by 15 mg/kg
Number of subjects: 227
Study 859943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent application three times weekly of INH 600 mg, rifampicin 750 mg, and myambutol 30 mg/kg for the first two months followed by 20 mg/kg
Number of subjects: 227
Study 859943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent application twice weekly of INH 800 mg, rifampicin 900 mg, and myambutol 50 mg/kg for the first two months followed by 30 mg/kg
Number of subjects: 227
Study 859943 — intervention group
Group type: COMPARATOR
Intervention: Control group treated by daily application of Str one gram for 6-8 months, INH 5-10 mg/kg and PAS 12-15 g daily
Number of subjects: 227
Study 859943 — intervention group
Group type: COMPARATOR
Intervention: All groups (A, B1, B2) compared to classical mode of treatment
Number of subjects: 227
Study 859943 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up of all groups
Number of subjects: 227
Study 31219898 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral Prophylactic Dressings (SPDs)
Number of subjects: 0
Study 28741576 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNERGY bioabsorbable polymer‐coated everolimus‐eluting stent
Number of subjects: 412
Study 28741576 — intervention group
Group type: COMPARATOR
Intervention: PROMUS Element Plus permanent polymer‐coated everolimus‐eluting stent
Number of subjects: 412
Study 25479982 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant load at 25W, 50W, 75W, 100W, 125W
Number of subjects: 209
Study 25479982 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematically varied loads (increased or decreased by steps of 25W) with overall loads kept constant at 50W, 75W, or 100W
Number of subjects: 209
Study 22521543 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 7808
Study 21961467 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational plus behavioral skills intervention (17-week program)
Number of subjects: 679